Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 33 of 102, showing 5 Applications out of 509 total, starting on record 161, ending on 165

# Protocol No Study Title Investigator(s) & Site(s)

161.

ECCT/18/07/07   A Randomized, Open, Parallel-group, Single Dose, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel in combination with Ferroquine (FQ) and FQ alone, in African Patients with Unc
    A Randomized, Open label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel (OZ439) given in combination with Ferroquine (FQ) and FQ alone, in African Patients with Uncomplicated Plasmodium falciparum Malaria   
Principal Investigator(s)
1. GRACE KIRINGA KAGUTHI
Site(s) in Kenya
1. Center for Respiratory Diseases Research (Siaya county)
2. KEMRI (Kisumu county)
 
View

162.

ECCT/19/01/01   A Randomized, Open, Parallel-group, Single Dose, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel in combination with Ferroquine (FQ) and FQ alone, in African Patients with Unc
    A Randomized, Open label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel (OZ439) given in combination with Ferroquine (FQ) and FQ alone, in African Patients with Uncomplicated Plasmodium falciparum Malaria   
Principal Investigator(s)
1. Bernhards Ogutu Ragama
Site(s) in Kenya
1. Ahero County hospital (Kisumu county)
2. Siaya County Hospital (Siaya county)
 
View

163.

ECCT/16/11/05   RV 456: Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo
    A randomized, obsever-blind, placebo controlled, two-part, Phase 2 study to evaluate the Safety, Tolerability and Immunogenicity of Two prime-boost regimen of the candidate Prophylactic vaccines for Ebola Ad26-ZEBOV and MVA-BN Filo.   
Principal Investigator(s)
1. Fredrick Kipyego Sawe
Site(s) in Kenya
1. KEMRI/WRP Kericho (Kericho county)
2. KEMRI/WRP Kombewa, Kisumu (Kisumu county)
 
View

164.

ECCT/16/11/04   RV456
    A Randomized, Observer-blind, Placebo-controlled, Two part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo   
Principal Investigator(s)
1. JANET OYIEKO
Site(s) in Kenya
KOMBEWA CLINICAL RESEARCH CENTRE
 
View

165.

ECCT/15/05/01   Janssen Ebola vaccine study
    A Randomized, Observer-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults, Including Elderly Subjects, HIV-infected Subjects, and Healthy Children in Two Age Strata in Africa   
Principal Investigator(s)
1. Prof Omu Aggrey Anzala
Site(s) in Kenya
KAVI –Institute of Clinical Research
 
View